(19)

(11)

EP 4 436 595 A1

(12)

(43) Date of publication: 02.10.2024 Bulletin 2024/40 (21) Application number: 22814525.6 (22) Date of filing: 18.11.2022

(51) International Patent Classification (IPC):  A61K 39/12(2006.01) C07K 16/08(2006.01) A61P 31/14(2006.01) A61K 39/00(2006.01) (52) Cooperative Patent Classification (CPC): A61K 39/12; A61P 31/14; C12N 2770/20034; C12N 2770/20022; A61K 2039/53; A61K 2039/575; C07K 16/08; C07K 2317/33 (86) International application number: PCT/IB2022/061148 (87) International publication number: WO 2023/089556 (25.05.2023 Gazette 2023/21)

(84) Designated Contracting States: AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC ME MK MT NL NO PL PT RO RS SE SI SK SM TR Designated Extension States: BA Designated Validation States: KH MA MD TN (30) Priority: 22.11.2021 US 202163282170 P (71) Applicant: Pfizer Inc. New York, NY 10001-2192 (US)

(72) Inventors: AGOSTINO, Michael John Andover, Massachusetts 01810 (US) ARAT, Seda Groton, Connecticut 06340 (US) CAUBEL, Patrick Michel Collegeville, Pennsylvania 19426 (US) GOSINK, Mark Matthew Groton, Connecticut 06340 (US) KHAN, Kanwar Nasir Mahmood Groton, Connecticut 06340 (US) KOZA-TAYLOR, Petra Helen Groton, Connecticut 06340 (US) MARTIN, Matthew Thomas Groton, Connecticut 06340 (US) (74) Representative: Pfizer  European Patent Department 23-25 avenue du Docteur Lannelongue 75668 Paris Cedex 14 75668 Paris Cedex 14 (FR)